Stevanato Group Delivers €1.186B Sales Growth and Targets €1.26–1.29B in 2026
Stevanato Group reported fiscal 2025 revenue of €1.186 billion, up 7%, with high-value solutions at 46% of total and adjusted diluted EPS rising 13% to €0.54. Q4 revenue grew 5% to €346.5 million, adjusted EBITDA margin widened by 70 basis points to 28.2%, with 2026 guidance of €1.26–€1.29 billion and €0.59–€0.63 EPS.
1. Full-Year 2025 Results
Stevanato Group closed fiscal 2025 with revenue of €1.186 billion, up 7% year-over-year (9% at constant currency), driven by a favorable mix of high-value solutions. Gross profit margin expanded 160 basis points to 29.0% and adjusted EBITDA margin rose 160 basis points to 25.1%, while diluted EPS increased to €0.51 and adjusted EPS to €0.54.
2. Fourth Quarter Highlights
In Q4 2025, revenue reached €346.5 million, up 5% (7% at constant currency), with high-value solutions representing 49% of total sales. Gross profit margin improved by 120 basis points to 30.9%, adjusted EBITDA margin rose to 28.2%, and net profit was €47.6 million with adjusted EPS of €0.18.
3. Segment Performance
The Biopharmaceutical and Diagnostic Solutions segment generated €307.1 million in Q4, up 10% (13% CC), led by a 31% increase in high-value solutions to €171.4 million. Engineering segment revenue declined 23% to €39.4 million, reflecting lower glass converting and assembly line projects.
4. 2026 Financial Guidance
For fiscal 2026, the company projects revenue of €1.26–€1.29 billion, adjusted EBITDA of €331.8–€346.9 million, and adjusted diluted EPS of €0.59–€0.63, supported by existing cash, operating cash flow and available credit lines.